CoChat
Sign Up
Cited by 14Schizophrenia research and treatmentMental Health and PsychiatryTreatment of Major Depression

The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.

Effects of antipsychotics on insight in schizophrenia: results from independent samples of first-episode and acutely relapsed patients

Misiak, Błażej, Frydecka, Dorota, Beszłej, Jan A., Moustafa, Ahmed A., Tybura, Piotr, Kucharska-Mazur, Jolanta, Samochowiec, Agnieszka, Bieńkowski, Przemysław, Samochowiec, Jerzy·2016·International Clinical Psychopharmacology
DOI 10.1097/yic.0000000000000120
Open this paper in CoChat — free account

Abstract

We aimed to investigate whether antipsychotics differentially impact insight and whether these effects appear because of improvement in psychopathological manifestation in 132 first-episode schizophrenia patients and 201 acutely relapsed schizophrenic patients, who were followed up for 12 weeks. Olanzapine and risperidone were administered to first-episode schizophrenia patients, whereas acutely relapsed schizophrenic patients were treated with olanzapine, perazine and ziprasidone. The Positive And Negative Syndrome Scale (PANSS) was used to assess psychopathology. Insight was assessed using the G12 item of PANSS. Unadjusted mixed-model regression analysis indicated a significant improvement in the PANSS G12 item score in both groups. There were no significant differences between distinct treatment subgroups of patients in terms of improvement in the PANSS G12 item score. After adjustment for the trajectories of changes in symptom dimensions, a decrease in the PANSS G12 item score was because of an improvement in positive, negative and excitement symptoms. A decrease in the PANSS G12 item score was also related to an increase in the severity of depressive symptomatology. Our results indicate that antipsychotics exert similar effects on insight in acute psychosis. These effects are likely because of an improvement in psychopathological manifestation. The improvement in insight might be related to the development of depressive symptoms.

Overview

Integrity signals

Registry

Crossref · 10.1097/yic.0000000000000120

Cites

45 of 45 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 45 references

Research works printed but not linked: 3

  1. Adamowski, 2012, Psychiatr Pol, 46, 985
  2. Kiejna, 2010, Psychiatr Pol, 44, 427
  3. Leucht, 2014, Cochrane Database Syst Rev, 1, CD002832

Cited by

Sorted by citations

Related

See all

Metadata

Authors
Misiak, B., Frydecka, D., Beszłej, J. A., Moustafa, A. A., Tybura, P., Kucharska-Mazur, J., Samochowiec, A., Bieńkowski, P., & Samochowiec, J.
Affiliations
University of Szczecin (PL)
Corresponding author
Misiak, Błażej
ORCID
Venue
International Clinical Psychopharmacology
Publisher
Ovid Technologies (Wolters Kluwer Health)
Published
2016-07
Volume
31
Issue
4
Pages
185-191
ISSN
0268-1315 (ISSN-L)
DOI
10.1097/yic.0000000000000120
OpenAlex
W2330454185
Cited by
14
References
45
Citations by year
2023: 3 · 2021: 4 · 2019: 2 · 2018: 3 · 2017: 2
FWCI
2.07
Type
journal article
Language
en
Open access
closed
Locations
  • International Clinical Psychopharmacology (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
  • Social Sciences › Arts and Humanities › Philosophy › Mental Health and Psychiatry
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
Keywords
antipsychotic drugs, insight, schizophrenia, first-episode schizophrenia, acute relapse, olanzapine, risperidone, perazine, ziprasidone, depressive symptoms, positive symptoms, negative symptoms
MeSH terms
Olanzapine, Adult, Benzodiazepines, Drug Therapy, Combination, Female, Follow-Up Studies, Humans, Male, Middle Aged, Psychiatric Status Rating Scales, Recurrence, Schizophrenia, Antipsychotic Agents, Treatment Outcome, Risperidone, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review